Home / Products / 3D stack Brain-on-a-Chip - SH-SY5Y model
3D stack Brain-on-a-Chip - SH-SY5Y model
3D stack Brain-on-a-Chip - SH-SY5Y model
3D stack Brain-on-a-Chip - SH-SY5Y model
3D stack Brain-on-a-Chip - SH-SY5Y model

3D stack Brain-on-a-Chip - SH-SY5Y model

£0.00
Specification 
Number of liver-chips per plate24 chips per plate. Each chip contains 1 cell layer
CellsDifferentiated SH-SY5Y cells
*other cell types on request 
Organ platfromCELLBLOCKS® 3D layout Liver-on-a-Chip model

3D stack Brain-chip - differentiated SH-SY5Y model

Characterisation Data 

Enhanced Hepatic Function on 3D Stack Liver Model

Imaging of cells through 3D stacked liver-chip layers

Cells were imaged live on day 3 in stacked layers using epi-fluorescent microscopy (10x magnification). Labling: HUVEC with Cell Tracker (Green, CMFDA), HepG2 cells with Cell Tracker (Red, CMTPX) and NIN/3T3 cells with Hoechst stain. Cells can be easy imaged through layers by standard inverted microscope

Metabolism in HepG2 hepatocytes

CYP3A4 expression levels in monoculture hepatocytes vs. tri-culture stacked set-up in CELLBLOKS®. In HepG2 heptocyes CYP3A4 activity increased 3 times compared to HepG2 monocultures.

Metabolism in human upcyte® primary hepatocytes

CYP3A4 expression levels in monoculture hepatocytes vs. tri-culture stacked set-up in CELLBLOKS®. In tri-culture model CYP3A4 in primary hepatocytes is enhanced by up to 3 times compared to monoculture hepatocytes over the 12 day of culture

Powerful Drug Induced Liver Injury (DILI) prediction capability

CELLBLOKS® 3D stack Liver-on-a-Chip model clearly distinguishes between hepatotoxic vs. their no-toxic structural analogues drugs at clinically relevant concentrations

Hepatotoxicity evaluation (24 h exposure) in CELLBLOKS®  NANOSTACK™ based 3D liver model

Hepatotoxic drug-induced toxicity in HepG2 cells can be detected at concentrations < 10 µM over human plasma Cmax levels. The model correctly differentiated the hepatotoxic effects of compounds at high DILI concern (Clozapine, Troglitazone, Trovafloxacin) as opposed to their non-toxic drug analogues (respectively Olanzapine, Pioglitazone, Levofloxacin) at clinically relevant concentrations, therefore demonstrating a robust DILI prediction capability.

Frequency Bought Together